Oestrogens for preventing recurrent urinary tract infection in postmenopausal women - PubMed
- ️Tue Jan 01 2008
Review
Oestrogens for preventing recurrent urinary tract infection in postmenopausal women
C Perrotta et al. Cochrane Database Syst Rev. 2008.
Abstract
Background: Recurrent urinary tract infection (RUTI) is defined as three episodes of urinary tract infection (UTI) in the previous 12 months or two episodes in the last six months. The main factors associated with RUTI in postmenopausal women are vesical prolapse, cystocoele, post-voidal residue and urinary incontinence, all associated with a decrease in oestrogen. The use of oestrogens to prevent RUTI has been proposed.
Objectives: To estimate the efficacy and safety of oral or vaginal oestrogens for preventing RUTI in postmenopausal women.
Search strategy: We searched the Cochrane Renal Group's specialised register, the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE (from 1950), EMBASE (from 1980), reference lists of articles without language restriction. Date of last search: February 2007.
Selection criteria: Randomised controlled trials (RCTs) in which postmenopausal women (more than 12 months since last menstrual period) diagnosed with RUTI received any type of oestrogen (oral , vaginal) versus placebo or any other intervention were included.
Data collection and analysis: Authors extracted data and assessed quality. Statistical analyses were performed using the random effects model and the results expressed as relative risk (RR) for dichotomous outcomes or mean difference (WMD) for continuous data with 95% confidence intervals (CI).
Main results: Nine studies (3345 women) were included. Oral oestrogens did not reduce UTI compared to placebo (4 studies, 2798 women: RR 1.08, 95% CI 0.88 to 1.33). Vaginal oestrogens versus placebo reduced the number of women with UTIs in two small studies using different application methods. The RR for one was 0.25 (95% CI 0.13 to 0.50) and 0.64 (95% CI 0.47 to 0.86) in the second. Two studies compared oral antibiotics versus vaginal oestrogens (cream (1), pessaries (1)). There was very significant heterogeneity and the results could not be pooled. Vaginal cream reduced the proportion of UTIs compared to antibiotics in one study and in the second study antibiotics were superior to vaginal pessaries. Adverse events for vaginal oestrogens were breast tenderness, vaginal bleeding or spotting, nonphysiologic discharge, vaginal irritation, burning and itching.
Authors' conclusions: Based on only two studies comparing vaginal oestrogens to placebo, vaginal oestrogens reduced the number of UTIs in postmenopausal women with RUTI, however this varied according to the type of oestrogen used and the treatment duration.
Comment in
-
Oestrogens for preventing recurrent urinary tract infection in postmenopausal women.
Perrotta C, Aznar M, Mejia R, Albert X, Ng CW. Perrotta C, et al. Obstet Gynecol. 2008 Sep;112(3):689-90. doi: 10.1097/AOG.0b013e318185f7a5. Obstet Gynecol. 2008. PMID: 18757671 No abstract available.
Similar articles
-
Interventions for preventing recurrent urinary tract infection during pregnancy.
Schneeberger C, Geerlings SE, Middleton P, Crowther CA. Schneeberger C, et al. Cochrane Database Syst Rev. 2015 Jul 26;2015(7):CD009279. doi: 10.1002/14651858.CD009279.pub3. Cochrane Database Syst Rev. 2015. PMID: 26221993 Free PMC article. Review.
-
Local oestrogen for vaginal atrophy in postmenopausal women.
Lethaby A, Ayeleke RO, Roberts H. Lethaby A, et al. Cochrane Database Syst Rev. 2016 Aug 31;2016(8):CD001500. doi: 10.1002/14651858.CD001500.pub3. Cochrane Database Syst Rev. 2016. PMID: 27577677 Free PMC article. Review.
-
Interventions for preventing recurrent urinary tract infection during pregnancy.
Schneeberger C, Geerlings SE, Middleton P, Crowther CA. Schneeberger C, et al. Cochrane Database Syst Rev. 2012 Nov 14;11:CD009279. doi: 10.1002/14651858.CD009279.pub2. Cochrane Database Syst Rev. 2012. PMID: 23152271 Updated. Review.
-
Local oestrogen for vaginal atrophy in postmenopausal women.
Suckling J, Lethaby A, Kennedy R. Suckling J, et al. Cochrane Database Syst Rev. 2006 Oct 18;(4):CD001500. doi: 10.1002/14651858.CD001500.pub2. Cochrane Database Syst Rev. 2006. PMID: 17054136 Updated. Review.
-
Antibiotics for preventing recurrent urinary tract infection in non-pregnant women.
Albert X, Huertas I, Pereiró II, Sanfélix J, Gosalbes V, Perrota C. Albert X, et al. Cochrane Database Syst Rev. 2004;2004(3):CD001209. doi: 10.1002/14651858.CD001209.pub2. Cochrane Database Syst Rev. 2004. PMID: 15266443 Free PMC article. Review.
Cited by
-
Sex and Gender Differences in Bacterial Infections.
Dias SP, Brouwer MC, van de Beek D. Dias SP, et al. Infect Immun. 2022 Oct 20;90(10):e0028322. doi: 10.1128/iai.00283-22. Epub 2022 Sep 19. Infect Immun. 2022. PMID: 36121220 Free PMC article. Review.
-
Olson PD, McLellan LK, Hreha TN, Liu A, Briden KE, Hruska KA, Hunstad DA. Olson PD, et al. Kidney Int. 2018 Sep;94(3):502-513. doi: 10.1016/j.kint.2018.04.023. Epub 2018 Jul 3. Kidney Int. 2018. PMID: 30041870 Free PMC article.
-
A healthy bladder: a consensus statement.
Lukacz ES, Sampselle C, Gray M, Macdiarmid S, Rosenberg M, Ellsworth P, Palmer MH. Lukacz ES, et al. Int J Clin Pract. 2011 Oct;65(10):1026-36. doi: 10.1111/j.1742-1241.2011.02763.x. Int J Clin Pract. 2011. PMID: 21923844 Free PMC article.
-
What Is Genitourinary Syndrome of Menopause and Why Should We Care?
Peters KJ. Peters KJ. Perm J. 2021 May;25:20.248. doi: 10.7812/TPP/20.248. Perm J. 2021. PMID: 33970091 Free PMC article.
-
Interventions for preventing recurrent urinary tract infection during pregnancy.
Schneeberger C, Geerlings SE, Middleton P, Crowther CA. Schneeberger C, et al. Cochrane Database Syst Rev. 2015 Jul 26;2015(7):CD009279. doi: 10.1002/14651858.CD009279.pub3. Cochrane Database Syst Rev. 2015. PMID: 26221993 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical